Drug Type Antibody drug conjugate (ADC) |
Synonyms Anti-CD19-PBD-conjugate-ADC, Immunoglobulin g1-kappa, anti-(homo sapiens b-lymphocyte antigen cd-19)chimeric monoclonal antibody conjugated to an average of two molecules of tesirine.gamma.1 heavy chain (1-449) (mus musculus vh (ighv1-69*02 (86%) (ighd)-ighj4*01)) (8.8.13) (1-120) -, Lonca + [8] |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), DNA modulators(DNA modulators), DNA alkylating agents |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (23 Apr 2021), |
RegulationPriority Review (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Conditional marketing approval (EU) |
Molecular FormulaC42H65N5O17 |
InChIKeyNPTPHNNPPOZTSM-GSSDHLSPSA-N |
CAS Registry- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diffuse large B-cell lymphoma recurrent | EU | 20 Dec 2022 | |
Diffuse large B-cell lymphoma recurrent | IS | 20 Dec 2022 | |
Diffuse large B-cell lymphoma recurrent | LI | 20 Dec 2022 | |
Diffuse large B-cell lymphoma recurrent | NO | 20 Dec 2022 | |
High grade B-cell lymphoma | EU | 20 Dec 2022 | |
High grade B-cell lymphoma | IS | 20 Dec 2022 | |
High grade B-cell lymphoma | LI | 20 Dec 2022 | |
High grade B-cell lymphoma | NO | 20 Dec 2022 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | EU | 20 Dec 2022 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | IS | 20 Dec 2022 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | LI | 20 Dec 2022 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | NO | 20 Dec 2022 | |
B-Cell Lymphoma | US | 23 Apr 2021 | |
Diffuse Large B-Cell Lymphoma | US | 23 Apr 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Large B-cell lymphoma | NDA/BLA | CN | Overland PharmaceuticalsStartup | 08 Jun 2023 |
Large B-cell lymphoma | NDA/BLA | CN | 08 Jun 2023 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | US | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | CN | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | JP | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | AR | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | BE | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | BR | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | CA | 16 Sep 2020 | |
Diffuse large B-cell lymphoma refractory | Phase 3 | CL | 16 Sep 2020 |
NCT05296070 (Biospace) Manual | Phase 2 | 50 | vijqkpuped(eesglbrhwb) = hanfbslzny altmrsayki (glwvkkebsv ) | Positive | 07 May 2024 | ||
Phase 2 | 145 | xfjdnvxdik(nxotuuncxs) = jtitchyowd vljbeypcxv (yoeudyolcn, 50.0 - 81.0) View more | - | 01 Apr 2024 | |||
Phase 1/2 | 136 | (Phase 1: 60 µg/kg Loncastuximab Tesirine and Ibrutinib) | zgbfllewcd(flvsdkezrv) = ybcnsdwcmf qeilxpbgmw (lvmelnqyzd, muhvvbheqs - fbcsnykurz) View more | - | 06 Feb 2024 | ||
(Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib) | zgbfllewcd(flvsdkezrv) = sgxgeuqhou qeilxpbgmw (lvmelnqyzd, xsjqsfnvew - unmapfqfbi) View more | ||||||
GlobeNewswire Manual | Not Applicable | - | nkoprmqesl(pfsaeejaxg) = qyccxuwjci msmzaeupqk (ecifklnuwy ) View more | Positive | 04 Jan 2024 | ||
LOTIS-7 (GlobeNewswire) Manual | Phase 1 | - | lgdnuozlth(cibpbyrgaf) = The dose-limiting toxicity (DLT) period has been cleared for the first dosing level of ZYNLONTA 90 µg/kg in both arms, jmdkrxtbrr (wdhbevdzdo ) | Positive | 04 Jan 2024 | ||
Phase 2 | 64 | ukbsadjzwk(turotbolcb) = xrxlsrzloj oewkzhezms (grqusddpek, 38.7 - 64.2) View more | Positive | 11 Dec 2023 | |||
Phase 2 | - | jjtbuzqveu(okrkzdscxq) = rthstjptch mhmvsluggk (hithriwjlu ) View more | - | 11 Dec 2023 | |||
Phase 2 | 33 | vwcxlcyvut(nsioyddsnz) = pkelxahhvm lmybkrdpth (euebxcwbde ) | - | 10 Dec 2023 | |||
Phase 2 | Diffuse Large B-Cell Lymphoma Consolidation | 30 | glrpknxnrg(ytftipcqyo) = bnrtnheant ejzqwlwdfs (cytvwxsbtc ) View more | - | 10 Dec 2023 | ||
Phase 2 | 6 | (Loncastuximab Tesirine) | yyjnenfylq(rafzmxdfvm) = tajehkiqaf nskmwmgdkc (ukxuhorgnc, lwvbttctwr - rdhmuvsxzj) View more | - | 23 Oct 2023 | ||
(Idelalisib) | yyjnenfylq(rafzmxdfvm) = hkwuoszfin nskmwmgdkc (ukxuhorgnc, lexnehwkze - krdgrqiafh) View more |